yingweiwo

Raf

Raf

Raf kinases are a family of three serine/threonine-specific protein kinases that are related to retroviral oncogenes.Rapidly Accelerated Fibrosarcoma is referred to as RAF. The RAS-RAF-MEK-ERK signal transduction cascade, also known as the mitogen-activated protein kinase (MAPK) cascade, involves Raf kinases. Interaction with RAS-GTPases is necessary for RAF kinase activation. A-RAF, B-RAF, and C-RAF (Raf-1) are the three members of the RAF kinase family. The B-Raf protein is involved in transmitting signals within cells that control cell growth.It was demonstrated that it was flawed (mutated) in a few human cancers. The RAF1 gene in humans encodes the enzyme C-RAF, also known as Raf-1. The c-Raf protein is a MAP kinase kinase (MAP3K) that works after the Ras subfamily of membrane-associated GTPases. It is a component of the ERK1/2 pathway. C-Raf is a member of the TKL (Tyrosine-kinase-like) group of protein kinases and belongs to the Raf kinase family of serine/threonine-specific protein kinases.

Raf related products

Structure Cat No. Product Name CAS No. Product Description
(Z)-GW-5074 V50935 (Z)-GW-5074 1233748-60-1 c-Raf inhibitor
3-(二甲基氨基)-N-[3-[(4-羟基苯甲酰基)氨基]-4-甲基苯基]苯甲酰胺 V1009 ZM 336372 208260-29-1 ZM 336372 (ZM-336372; ZM336372) is a novel, potent and selective c-Raf kinase inhibitor with potential anticancer activity.
AD80 V2761 AD80 1384071-99-1 AD80 is a novel multikinase inhibitor that shows strong activity against human RET, BRAF, S6K, and SRC but were much less active than either AD57 or AD58 against mTOR.
Agerafenib (CEP-32496; RXDX-105; AC013773) V1013 Agerafenib (CEP-32496; RXDX-105; AC013773) 1188910-76-0 Agerafenib (formerly RXDX105; AC013773;RXDX-105;CEP-32496;AC-01377)is a potent and orally bioactive inhibitor of BRAFV600E and c-Raf with potential antitumor activity.
Avutometinib potassium V97930 Avutometinib potassium 946128-90-1 Avutometinib (CH5126766) (potassium) is a RAF/MEK clamp that effectively inhibits RAF/MEK kinase activity, induces RAF-MEK negative complex, and blocks phosphorylation of MEK by ARAF, BRAF, and CRAF.
AZ 628 (AZ-628; AZ628) V1006 AZ 628 (AZ-628; AZ628) 878739-06-1 AZ-628 (AZ628; AZ 628) is a novel, selective, and orally bioavailable Raf inhibitor with potential antineoplastic activity.
B-Raf IN 13 V74131 B-Raf IN 13 2573782-74-6 B-Raf IN 13 is a BRAF inhibitor (antagonist) with IC50 of 3.55 nM in the BRAF V600E enzyme assay.
B-Raf IN 14 V74141 B-Raf IN 14 326918-98-3 B-Raf IN 14 (Comp 25) is a BRAF inhibitor (antagonist) with IC50 of 11.08 μM and may be utilized in cancer-related research.
B-Raf IN 16 V74147 B-Raf IN 16 2304746-24-3 B-Raf IN 16 (Compound I) is a BRAF inhibitor belonging to the cyclic iminopyrimidine analogues.
B-Raf IN 2 V74133 B-Raf IN 2 2649372-20-1 B-Raf IN 2 is a potent and specific BRAF inhibitor for cancer-related research.
B-Raf inhibitor 1 V3442 B-Raf inhibitor 1 1093100-40-3 B-Raf inhibitor 1 is a novel, potent and selectiveRafkinase inhibitor withKis of 1 nM, 1 nM, and 0.3 nM for B-RafWT, B-RafV600E, and C-Raf, respectively.
Belvarafenib TFA (HM95573 TFA; GDC-5573 TFA; RG6185 TFA) V74139 Belvarafenib TFA (HM95573 TFA; GDC-5573 TFA; RG6185 TFA) 2443966-84-3 Belvarafenib TFA (HM95573 TFA) is a potent, broad inhibitor of rapidly accelerating fibrosarcoma kinase (RAF) with IC50s of 56 nM, 7 nM and C-RAF for B-RAF, B-RAFv600E and C-RAF, respectively.
BI-882370 V4710 BI-882370 1392429-79-6 BI-882370 (BI 882370), structurally similar to vermurafenib, is a novel, highly potent and selective BRAF inhibitor with anticancer activity.
Braftide V87104 Braftide 2411851-64-2 Braftide is an allosteric inhibitor of BRAF kinase that inhibits the formation of BRAF dimers by targeting the surface of BRAF kinase dimers.
BRAFV600E-IN-1 V94072 BRAFV600E-IN-1 BRAFV600E-IN-1 (Compound 9S) is a BRAF inhibitor.
Brimarafenibum V99901 Brimarafenibum 1643326-82-2 Brimarafenib is a rapidly accelerating fibrosarcoma (Raf) kinase inhibitor with antitumor effects.
CCT196969 V2661 CCT196969 1163719-56-9 CCT196969 (CCT-196969) is a novel, orally bioavailable, pan-RAF inhibitor (IC50 = 0.1 μM) with anti-SRC and anticancer activity.
CID-25014542 V6701 CID-25014542 220904-99-4 Raf inhibitor 2 is a potent raf kinase inhibitor (IC50<1.0 μM), compound 32, developed from EP1003721B1 patent.
Dabrafenib-d9 (GSK2118436A-d9; GSK2118436-d9) V74145 Dabrafenib-d9 (GSK2118436A-d9; GSK2118436-d9) 1423119-98-5 Dabrafenib-d9 is the deuterated form of dabrafenib.
Doramapimod hydrochloride V94037 Doramapimod hydrochloride 1283526-53-3 Doramamod hydrochloride (BIRB 796 hydrochloride) is an anti-inflammatory compound that exhibits biological activity through inhibition of p38 MAPK.
Contact Us